174 related articles for article (PubMed ID: 37982648)
1. CRISPR-Cas attack of HIV-1 proviral DNA can cause unintended deletion of surrounding cellular DNA.
Liu Y; Binda CS; Berkhout B; Das AT
J Virol; 2023 Dec; 97(12):e0133423. PubMed ID: 37982648
[TBL] [Abstract][Full Text] [Related]
2. Elimination of infectious HIV DNA by CRISPR-Cas9.
Das AT; Binda CS; Berkhout B
Curr Opin Virol; 2019 Oct; 38():81-88. PubMed ID: 31450074
[TBL] [Abstract][Full Text] [Related]
3. Gene Therapy with CRISPR/Cas9 Coming to Age for HIV Cure.
Soriano V
AIDS Rev; 2017; 19(3):167-172. PubMed ID: 29019352
[TBL] [Abstract][Full Text] [Related]
4. Transient CRISPR-Cas Treatment Can Prevent Reactivation of HIV-1 Replication in a Latently Infected T-Cell Line.
Liu Y; Jeeninga RE; Klaver B; Berkhout B; Das AT
Viruses; 2021 Dec; 13(12):. PubMed ID: 34960730
[TBL] [Abstract][Full Text] [Related]
5. A Combinatorial CRISPR-Cas9 Attack on HIV-1 DNA Extinguishes All Infectious Provirus in Infected T Cell Cultures.
Wang G; Zhao N; Berkhout B; Das AT
Cell Rep; 2016 Dec; 17(11):2819-2826. PubMed ID: 27974196
[TBL] [Abstract][Full Text] [Related]
6. CRISPR-CAS Replacing Antiviral Drugs against HIV: An Update.
Hashmat R; Yousaf MZ; Rahman Z; Anjum KM; Yaqoob A; Imran M
Crit Rev Eukaryot Gene Expr; 2020; 30(1):77-83. PubMed ID: 32421986
[TBL] [Abstract][Full Text] [Related]
7. CRISPR/Cas9 Ablation of Integrated HIV-1 Accumulates Proviral DNA Circles with Reformed Long Terminal Repeats.
Lai M; Maori E; Quaranta P; Matteoli G; Maggi F; Sgarbanti M; Crucitta S; Pacini S; Turriziani O; Antonelli G; Heeney JL; Freer G; Pistello M
J Virol; 2021 Nov; 95(23):e0135821. PubMed ID: 34549986
[TBL] [Abstract][Full Text] [Related]
8. CRISPR-Cas9 Dual-gRNA Attack Causes Mutation, Excision and Inversion of the HIV-1 Proviral DNA.
Binda CS; Klaver B; Berkhout B; Das AT
Viruses; 2020 Mar; 12(3):. PubMed ID: 32197474
[TBL] [Abstract][Full Text] [Related]
9. CRISPR-Cas9 Mediated Exonic Disruption for HIV-1 Elimination.
Herskovitz J; Hasan M; Patel M; Blomberg WR; Cohen JD; Machhi J; Shahjin F; Mosley RL; McMillan J; Kevadiya BD; Gendelman HE
EBioMedicine; 2021 Nov; 73():103678. PubMed ID: 34774454
[TBL] [Abstract][Full Text] [Related]
10. CRISPR-Cas12b enables a highly efficient attack on HIV proviral DNA in T cell cultures.
Fan M; Bao Y; Berkhout B; Herrera-Carrillo E
Biomed Pharmacother; 2023 Sep; 165():115046. PubMed ID: 37379644
[TBL] [Abstract][Full Text] [Related]
11. A combinational CRISPR/Cas9 gene-editing approach can halt HIV replication and prevent viral escape.
Lebbink RJ; de Jong DC; Wolters F; Kruse EM; van Ham PM; Wiertz EJ; Nijhuis M
Sci Rep; 2017 Feb; 7():41968. PubMed ID: 28176813
[TBL] [Abstract][Full Text] [Related]
12. Viral diversity is an obligate consideration in CRISPR/Cas9 designs for targeting the HIV reservoir.
Roychoudhury P; De Silva Feelixge H; Reeves D; Mayer BT; Stone D; Schiffer JT; Jerome KR
BMC Biol; 2018 Jul; 16(1):75. PubMed ID: 29996827
[TBL] [Abstract][Full Text] [Related]
13. Elimination of HIV-1 Genomes from Human T-lymphoid Cells by CRISPR/Cas9 Gene Editing.
Kaminski R; Chen Y; Fischer T; Tedaldi E; Napoli A; Zhang Y; Karn J; Hu W; Khalili K
Sci Rep; 2016 Mar; 6():22555. PubMed ID: 26939770
[TBL] [Abstract][Full Text] [Related]
14. A CRISPR-Cas Cure for HIV/AIDS.
Hussein M; Molina MA; Berkhout B; Herrera-Carrillo E
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36675077
[TBL] [Abstract][Full Text] [Related]
15. HIV-1 cure strategies: why CRISPR?
Atkins AJ; Allen AG; Dampier W; Haddad EK; Nonnemacher MR; Wigdahl B
Expert Opin Biol Ther; 2021 Jun; 21(6):781-793. PubMed ID: 33331178
[TBL] [Abstract][Full Text] [Related]
16. Live Visualization of HIV-1 Proviral DNA Using a Dual-Color-Labeled CRISPR System.
Ma Y; Wang M; Li W; Zhang Z; Zhang X; Wu G; Tan T; Cui Z; Zhang XE
Anal Chem; 2017 Dec; 89(23):12896-12901. PubMed ID: 29120617
[TBL] [Abstract][Full Text] [Related]
17. Synthetic gRNA/Cas9 Ribonucleoprotein Inhibits HIV Reactivation and Replication.
Khanal S; Cao D; Zhang J; Zhang Y; Schank M; Dang X; Nguyen LNT; Wu XY; Jiang Y; Ning S; Zhao J; Wang L; Gazzar ME; Moorman JP; Yao ZQ
Viruses; 2022 Aug; 14(9):. PubMed ID: 36146709
[TBL] [Abstract][Full Text] [Related]
18. Pathways Toward a Functional HIV-1 Cure: Balancing Promise and Perils of CRISPR Therapy.
Herskovitz J; Hasan M; Patel M; Kevadiya BD; Gendelman HE
Methods Mol Biol; 2022; 2407():429-445. PubMed ID: 34985679
[TBL] [Abstract][Full Text] [Related]
19. The CRISPR/Cas9 system inactivates latent HIV-1 proviral DNA.
Zhu W; Lei R; Le Duff Y; Li J; Guo F; Wainberg MA; Liang C
Retrovirology; 2015 Feb; 12():22. PubMed ID: 25808449
[TBL] [Abstract][Full Text] [Related]
20. A CRISPR/Cas9 guidance RNA screen platform for HIV provirus disruption and HIV/AIDS gene therapy in astrocytes.
Huang Z; Nair M
Sci Rep; 2017 Jul; 7(1):5955. PubMed ID: 28729655
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
